vs

Side-by-side financial comparison of Rexford Industrial Realty, Inc. (REXR) and Tarsus Pharmaceuticals, Inc. (TARS). Click either name above to swap in a different company.

Rexford Industrial Realty, Inc. is the larger business by last-quarter revenue ($245.1M vs $151.7M, roughly 1.6× Tarsus Pharmaceuticals, Inc.). Rexford Industrial Realty, Inc. runs the higher net margin — 0.5% vs -5.5%, a 6.0% gap on every dollar of revenue. On growth, Tarsus Pharmaceuticals, Inc. posted the faster year-over-year revenue change (128.4% vs -2.9%). Over the past eight quarters, Tarsus Pharmaceuticals, Inc.'s revenue compounded faster (134.4% CAGR vs 1.6%).

Genpact Ltd. is an American information technology services, consulting, and outsourcing company headquartered in New York City, New York. Founded in Gurgaon, India, and legally domiciled in Bermuda, Genpact employs more than 125,000 people and provides services to clients in over 30 countries worldwide. Genpact is listed on the NYSE and generated revenues of US$4.48 billion in 2023.

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

REXR vs TARS — Head-to-Head

Bigger by revenue
REXR
REXR
1.6× larger
REXR
$245.1M
$151.7M
TARS
Growing faster (revenue YoY)
TARS
TARS
+131.2% gap
TARS
128.4%
-2.9%
REXR
Higher net margin
REXR
REXR
6.0% more per $
REXR
0.5%
-5.5%
TARS
Faster 2-yr revenue CAGR
TARS
TARS
Annualised
TARS
134.4%
1.6%
REXR

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
REXR
REXR
TARS
TARS
Revenue
$245.1M
$151.7M
Net Profit
$1.2M
$-8.4M
Gross Margin
Operating Margin
41.0%
-5.3%
Net Margin
0.5%
-5.5%
Revenue YoY
-2.9%
128.4%
Net Profit YoY
27.7%
63.8%
EPS (diluted)
$0.38
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
REXR
REXR
TARS
TARS
Q1 26
$245.1M
Q4 25
$248.1M
$151.7M
Q3 25
$253.2M
$118.7M
Q2 25
$249.5M
$102.7M
Q1 25
$252.3M
$78.3M
Q4 24
$242.9M
$66.4M
Q3 24
$241.8M
$48.1M
Q2 24
$237.6M
$40.8M
Net Profit
REXR
REXR
TARS
TARS
Q1 26
$1.2M
Q4 25
$-8.4M
Q3 25
$89.9M
$-12.6M
Q2 25
$116.3M
$-20.3M
Q1 25
$71.2M
$-25.1M
Q4 24
$64.9M
$-23.1M
Q3 24
$67.8M
$-23.4M
Q2 24
$82.5M
$-33.3M
Operating Margin
REXR
REXR
TARS
TARS
Q1 26
41.0%
Q4 25
-5.3%
Q3 25
-12.2%
Q2 25
-21.6%
Q1 25
-33.5%
Q4 24
-36.8%
Q3 24
-52.3%
Q2 24
-81.6%
Net Margin
REXR
REXR
TARS
TARS
Q1 26
0.5%
Q4 25
-5.5%
Q3 25
35.5%
-10.6%
Q2 25
46.6%
-19.8%
Q1 25
28.2%
-32.1%
Q4 24
26.7%
-34.8%
Q3 24
28.0%
-48.7%
Q2 24
34.7%
-81.6%
EPS (diluted)
REXR
REXR
TARS
TARS
Q1 26
$0.38
Q4 25
$-0.17
Q3 25
$0.37
$-0.30
Q2 25
$0.48
$-0.48
Q1 25
$0.30
$-0.64
Q4 24
$0.26
$-0.57
Q3 24
$0.30
$-0.61
Q2 24
$0.37
$-0.88

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
REXR
REXR
TARS
TARS
Cash + ST InvestmentsLiquidity on hand
$51.7M
$417.3M
Total DebtLower is stronger
$72.4M
Stockholders' EquityBook value
$8.3B
$343.4M
Total Assets
$12.4B
$562.2M
Debt / EquityLower = less leverage
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
REXR
REXR
TARS
TARS
Q1 26
$51.7M
Q4 25
$165.8M
$417.3M
Q3 25
$249.0M
$401.8M
Q2 25
$431.1M
$381.1M
Q1 25
$504.6M
$407.9M
Q4 24
$56.0M
$291.4M
Q3 24
$61.8M
$317.0M
Q2 24
$125.7M
$323.6M
Total Debt
REXR
REXR
TARS
TARS
Q1 26
Q4 25
$3.3B
$72.4M
Q3 25
$3.2B
$72.3M
Q2 25
$3.3B
$72.1M
Q1 25
$3.3B
$72.0M
Q4 24
$3.3B
$71.8M
Q3 24
$3.4B
$71.7M
Q2 24
$3.3B
$71.6M
Stockholders' Equity
REXR
REXR
TARS
TARS
Q1 26
$8.3B
Q4 25
$8.5B
$343.4M
Q3 25
$8.7B
$335.1M
Q2 25
$8.8B
$332.6M
Q1 25
$8.8B
$342.5M
Q4 24
$8.3B
$224.5M
Q3 24
$8.1B
$237.5M
Q2 24
$8.0B
$252.2M
Total Assets
REXR
REXR
TARS
TARS
Q1 26
$12.4B
Q4 25
$12.6B
$562.2M
Q3 25
$12.9B
$534.6M
Q2 25
$13.1B
$495.0M
Q1 25
$13.1B
$500.8M
Q4 24
$12.6B
$377.0M
Q3 24
$12.4B
$376.3M
Q2 24
$12.4B
$376.8M
Debt / Equity
REXR
REXR
TARS
TARS
Q1 26
Q4 25
0.38×
0.21×
Q3 25
0.37×
0.22×
Q2 25
0.38×
0.22×
Q1 25
0.38×
0.21×
Q4 24
0.40×
0.32×
Q3 24
0.42×
0.30×
Q2 24
0.42×
0.28×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
REXR
REXR
TARS
TARS
Operating Cash FlowLast quarter
$19.3M
Free Cash FlowOCF − Capex
$13.0M
FCF MarginFCF / Revenue
8.6%
Capex IntensityCapex / Revenue
4.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
REXR
REXR
TARS
TARS
Q1 26
Q4 25
$542.1M
$19.3M
Q3 25
$149.6M
$18.3M
Q2 25
$128.2M
$-29.4M
Q1 25
$152.6M
$-20.7M
Q4 24
$478.9M
$-22.2M
Q3 24
$127.2M
$-8.7M
Q2 24
$101.7M
$-14.4M
Free Cash Flow
REXR
REXR
TARS
TARS
Q1 26
Q4 25
$208.7M
$13.0M
Q3 25
$60.5M
$16.3M
Q2 25
$45.0M
$-30.4M
Q1 25
$73.4M
$-21.2M
Q4 24
$105.5M
$-22.3M
Q3 24
$7.2M
$-8.9M
Q2 24
$16.5M
$-15.4M
FCF Margin
REXR
REXR
TARS
TARS
Q1 26
Q4 25
84.1%
8.6%
Q3 25
23.9%
13.8%
Q2 25
18.0%
-29.6%
Q1 25
29.1%
-27.1%
Q4 24
43.4%
-33.5%
Q3 24
3.0%
-18.6%
Q2 24
7.0%
-37.8%
Capex Intensity
REXR
REXR
TARS
TARS
Q1 26
Q4 25
134.4%
4.2%
Q3 25
35.2%
1.6%
Q2 25
33.3%
1.0%
Q1 25
31.4%
0.8%
Q4 24
153.7%
0.1%
Q3 24
49.6%
0.6%
Q2 24
35.8%
2.5%
Cash Conversion
REXR
REXR
TARS
TARS
Q1 26
Q4 25
Q3 25
1.66×
Q2 25
1.10×
Q1 25
2.14×
Q4 24
7.38×
Q3 24
1.88×
Q2 24
1.23×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons